

# Our History

[Home](#) > [About us](#) > [Our History](#)

## Our Successful Journey

True to the origin of our name, Metamorphosis, MorphoSys has transformed from an R&D technology provider into a global commercial-stage biopharmaceutical company.

### 1992

MorphoSys founded in Martinsried, Germany by Dr. Simon Moroney and Prof. Dr. Andreas Plückerthun

### 1994

Invention of the HuCAL Concept, synthetic library consisting of human antibody sequences for the generation of highly specific, fully human antibodies. Inventor: Achim Knappik, Dr. Simon Moroney, Prof. Dr. Andreas Plückerthun (and others)

### 1997

Move to IZB Gründerzentrum with ~30 employees; first partnership with Pharmacia & Upjohn

### 1999

MorphoSys is listed on the Frankfurt stock exchange; partnership with Bayer

### 2000

Move to our own building in Martinsried, ~100 employees

### 2000–2007

Growth through partnerships: Novartis, Janssen, Schering–Plough, Pfizer, Merck

### Since 2007

Own drug development, e.g. with Xencor, GSK and others

### 2016

Move to new building in Planegg: state-of-the-art office and lab, unifying all teams under one roof

### 2017

Tremfya® is the first drug based on MorphoSys' antibody technology to receive regulatory approval. Developed and marketed by Janssen for the treatment of plaque psoriasis

### 2018

MorphoSys is listed on NASDAQ; MorphoSys US Inc. is established; MorphoSys and I-Mab enter strategic development and commercialization agreement for MOR210/TJ210

### 2019

Jean–Paul Kress appointed as MorphoSys CEO in September

### January 2020

MorphoSys and Incyte enter into collaboration and licensing agreement to further develop and commercialize tafasitamab globally

### July 2020

The U.S. Food and Drug Administration (FDA) grants accelerated approval for Monjuvi® (tafasitamab–cxix) in combination with lenalidomide in patients with a certain type of lymphoma

### November 2020

MorphoSys and Cherry Biolabs entered into a licensing agreement for innovative, multispecific Hemibody technology; MorphoSys and Xencor enter into collaboration exploring further combinations with tafasitamab and Xencor's CD20xCD3 bispecific plamotamab

### July 2021

Acquisition of Constellation Pharmaceuticals, a U.S. biotech company that adds exciting, pioneering science and two new product candidates to our pipeline

### August 2021

Conditional approvals for Minjuvi® (tafasitamab) in the European Union and Canada in combination with lenalidomide in patients with a certain type of lymphoma

[Careers](#)

[Leadership](#)

[Pipeline](#)

[Medicines](#)

[Investors](#)

[Media](#)

